9 results about "Human organism" patented technology

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

The disclosure provides nucleic acid constructs comprising a transmembrane reporter cassette encoding an affinity tag, a transmembrane (TM) domain and a fluorescent reporter protein. In embodiments, the nucleic acid constructs are inserted in a safe harbor locus or an immunoglobulin constant domain locus of in a cell of a non-human mammal. In embodiments, when the transmembrane reporter cassette is expressed in the cell, the affinity tag is displayed on a surface of the cell while the fluorescent reporter protein is located inside the cell membrane. The presence of the affinity tag and the fluorescent reporter protein allow for identification, sorting and / or isolation of cells expressing the nucleic acid constructs. The disclosure also provides embodiments of methods of modifying cells and non-human organisms with the nucleic acid constructs, along with embodiments of cells and non-human organisms produced using the disclosed methods.

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

To provide devices, systems, and programs for evaluating a state of interstitial fluid, blood, urine, tears, sweat, saliva, food and beverages, brewed products, or the like of humans and non-human organisms, and to provide evaluation methods using the same.SOLUTION: The present invention provides: devices, systems, and programs for evaluating a state of a specimen, including an acting portion for applying lactate dehydrogenase to the specimen and a sensor for detecting the state of the specimen after the application of lactate dehydrogenase; a method for evaluating the state of the specimen using the same; and an enzyme used therein.SELECTED DRAWING: None

Described herein are non-human organisms for producing triacylglycerol wherein the non-human organism is genetically modified to express a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) and wherein, once expressed, the C16:0 LPAT is localised in the endoplasmic reticulum. Also described are non-human organisms for producing triacylglycerol in which (a) a lysophosphatidic acid acyltransferase specific for C16:0-Coenzyme A (C16:0 LPAT) is localised in the endoplasmic reticulum; and (b) activity of native endoplasmic reticulum lysophosphatidic acid acyltransferase (ER LPAT) is suppressed or prevented. Further described are non-human organisms in which a chloroplast lysophosphatidic acid acyltransferase (LPAT) is expressed, wherein said chloroplast LPAT lacks a functional chloroplast targeting signal. The disclosure also relates to methods for extracting triacylglycerol from the organisms and the use thereof in infant formula.

The invention relates to a pharmaceutical composition comprising at least one pharmaceutically active ingredient which is completely dissolved in a solvent phase, characterized in that the pharmaceutically active ingredient is in particular selected from the group of fluorinated heteroaryl amides and the solvent phase is formulated as a solvent mixture and comprises at least one first solvent and a second solvent which is different from the first solvent, wherein the first solvent comprises a C1 to C15-alcohol, wherein the second solvent comprises an organic carbonate, and wherein the first solvent is present in a proportion of 50 to 95 % by weight and wherein the second solvent is present in a proportion of 5 to 50 % by weight, in each case based on the sum of the solvents in the solvent phase.

The present invention relates to an optimized nucleic acid molecule encoding a Responder protein under the control of a promoter that is post-meiotically active during spermiogenesis, a host cell or non-human organism comprising the nucleic acid molecule as well as the production of a male or female transgenic non-human organism employing the nucleic acid molecule.

The present invention relates to a pharmaceutical composition comprising at least one pharmaceutically active ingredient that is completely soluble in a solvent phase, characterized in that the pharmaceutically active ingredient is in particular from the group of fluorinated heteroaryl amides, and the solvent phase is constituted as a solvent mixture and comprises at least one first solvent and a second solvent different from the first solvent, wherein the first solvent comprises a C1-C15 alcohol and the second solvent comprises an organic carbonate, and wherein the first solvent is present in a proportion of 50% to 95% by weight and the second solvent is present in a proportion of 5% to 50% by weight, in each case based on the total amount of solvents in the solvent phase.

The invention relates to a method for production of acetyl phosphate from renewable or next generation feedstocks, comprising enzymatically converting a non-phosphorylated carbohydrate into acetyl phosphate and a product, with a phosphoketolase. In embodiments, the phosphoketolase comprises at least one mutation in its active site preferably enabling an increased affinity and / or increased phosphoketolase activity for a non-phosphorylated carbohydrate, such as i) D-fructose, (ii) D-erythrulose or (iii) glycolaldehyde, compared to a wild- type phosphoketolase sequence. The invention further relates to a phosphoketolase enzyme comprising in its active site the mutation(s) H548N, N549D, H256Y, T2A:16T:H260Y:H548N, H548Y, H260Y:H548Y, H256Y:H260Y:H548Y, H142N:E153D and / or T2A:16T:H260Y:H548Y and its use for producing acetyl phosphate from a non-phosphorylated carbohydrate. The invention further relates to non-human organisms, preferably a microorganism, comprising a gene encoding and optionally expressing said phosphoketolase enzyme and compositions comprising the same.